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 INTRODUCTION 
 Diabetes reduces lifetime by about 6 years, compared with that of 
subjects without diabetes ( 1 ), because it increases the risks of death 
from all causes, including chronic liver diseases (CLDs) ( 2 – 4 ). A 
 ~ 2.5-fold higher risk of death from CLD was observed in a cohort 
study on 7,148 type 2 diabetes patients ( 5 ) as well as in a recent large 
study on more than one million subjects ( 6 ). It is known that CLD 
occurs due to diff erent etiologies, such as  alcohol and drug use, and 
viral, autoimmune, and metabolic causes. Nonalcoholic fatty liver 
disease (NAFLD), the most common cause of CLD among adults 
with or without type 2 diabetes in Western countries, has emerged 
as a public health problem of epidemic proportions worldwide ( 7 –
 9 ). Notably, patients with type 2 diabetes and NAFLD are also more 
likely to develop the more advanced forms of NAFLD, such as non-
alcoholic steatohepatitis, advanced fi brosis, cirrhosis, and, in some 
cases, hepatocellular carcinoma ( 7 ). In recent years, NAFLD has been 
recognized as a major risk factor of morbidity and mortality in type 2 
diabetes ( 10,11 ). It is noteworthy that the prevalence of NAFLD is 
increasing and keeping pace with the steady worldwide growth of 
obesity, type 2 diabetes, and the metabolic syndrome ( 12 ). How-
ever, although it is known that mortality from CLD is increased in 
subjects with diabetes, to our knowledge, no information is cur-
rently available about the etiology of CLD-related deaths in this 
patient population. 
 In fact, mortality statistics are generally limited to the underly-
ing cause of death. However, comorbidities are mentioned in death 
certifi cates and they might be used to provide a more compre-
hensive assessment of diseases that may contribute, more or less 
directly, to death. Th e analysis of all diseases reported on death 
certifi cates (multiple cause of death analysis) permits more exten-
sive capture of CLD-related deaths, and allows the retrieval of the 
etiology of CLD. Although suff ering from the underreporting of 
causes and types of liver diseases, the analysis of multiple causes 
of death data has been applied in US studies to assess the burden 
of hepatitis C virus (HCV) infection - and alcohol-related CLD in 
the overall population and in high-risk subgroups ( 13 ). Th e main 
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aim of our study was to analyze all information available in death 
certifi cates in an entire region in Italy to investigate the etiology of 
CLD-associated mortality in diabetes. 
 METHODS 
 Identifi cation and follow-up of a cohort of diabetic subjects 
 Th e Veneto Region (North-Eastern Italy) has about 4.9 million 
inhabitants; life expectancy is about 80 and 85 years in males and 
females, respectively, with circulatory diseases and cancer being 
the main causes of death. Hospital care is free of charge, although 
patients must contribute to out-of-hospital care and drug costs, 
unless they are aff ected by major chronic diseases, such as dia-
betes. Upon certifi cation from a specialist, subjects with diabetes 
receive disease-specifi c care without any contribution to the costs. 
Th ese subjects are listed in a regional electronic archive, which 
is a precious source for the identifi cation of subjects aff ected by 
diabetes. Th is archive is estimated to include about 80 % of sub-
jects identifi ed as diabetic by multiple data sources; in a previ-
ous survey in the Veneto Region, its positive predictive value was 
98 % for the diagnosis of diabetes in a sample of subjects aged 
18 – 65 years ( 14 ). Although the date of diabetes diagnosis was not 
available, the archive included the date of diabetes registration in 
electronic records: such dates could correspond to the develop-
ment of the electronic archive mainly in 1999 – 2000 and there-
fore could follow the diagnosis by several years, but allowed the 
identifi cation of a sub-cohort of patients (those registered before 
2001) who surely had at least 7 years of diabetes duration at the 
beginning of the follow-up. 
 In the Veneto Region, all death certifi cates are collected by the 
Local Health Units of the National Health Service and a copy of 
these is transmitted to the Regional Epidemiology Service. For the 
purpose of the present study, we identifi ed in the electronic archive 
of the Veneto Region  a cohort of diabetic patients aged 30 – 89 years 
who were exempt from medical charges for diabetes treatment in 
December 2007, and linked them with the electronic archive of 
causes of deaths that occurred in the period from 2008 to 2010. 
Th e record-linkage was performed on previously anonymized 
records, without any possibility of identifi cation of individuals. 
Th e informed consent requirement for this study was exempted by 
the ethics committee because researchers only accessed retrospec-
tively a de-identifi ed database for analysis purposes. Each subject 
was followed from 1 January 2008 either until death, or 90 years of 
age, or 31 December 2010, whichever came fi rst. 
 Analysis of multiple causes of death 
 As previously mentioned, a copy of the death certifi cates of all resi-
dents in the Veneto Region is centrally transmitted to the Regional 
Epidemiology Service for coding of causes of death according to 
the International Classifi cation of Diseases, 10th Edition. Since 
2008, the electronic regional archive of mortality includes not 
only the underlying cause of death but also all diseases mentioned 
in the death certifi cate, both in part I (i.e., conditions involved 
in the causal chain of events leading to death) and in part II (i.e., 
other signifi cant conditions contributing to death). 
 To identify CLD-related deaths, codes usually adopted in liver 
cirrhosis mortality statistics (K70, K73, K74) were selected in any 
position of the death certifi cate. Th e disease was further classi-
fi ed as being related to viral hepatitis infection (codes, B15-B19), 
to alcohol (codes for alcoholic liver diseases and for mental and 
behavioral disorders due to use of alcohol, K70 and F10), or to a 
non-viral non-alcohol-related etiology (NVNA-CLD). 
 Statistical analysis 
 Age-standardized mortality rates, using the direct method (European 
standard population), were computed among diabetics and the 
whole regional population for circulatory and neoplastic dis-
eases and for CLD. Standardized mortality ratios (SMRs) with 
95 % confi dence intervals, based on the Poisson distribution, were 
computed as the ratios between deaths observed in the diabetic 
cohort, and those expected according to age- and gender-spe-
cifi c regional mortality rates. SMRs were computed for both total 
mortality and the single nosologic categories on the basis of 
the underlying cause of death. Specifi cally, for CLD (overall, 
virus-related, alcohol-related, or NVNA-related), SMRs were 
also computed on the basis of all comorbidities reported in the 
death certifi cates. SMRs were assessed both in the whole cohort 
of diabetic subjects, separately by gender and three classes of 
age (adults,   <  65 years; young – old, 65 – 74 years; and elderly, 
 ≥ 75 years), and in the sub-cohort with a longer duration of disease 
at the beginning of the follow-up. 
 RESULTS 
 As detailed in  Figure 1 , 176,771 diabetic subjects were initially 
identifi ed in December 2007 from the regional electronic archive 
of exemptions from medical charge of the Veneto Region. Out of 
them, 209 were excluded because of incomplete data and 1,302 
because they died in the last weeks of the year. Out of the cohort 
of 173,260 patients with complete data and alive on 31 December 
2007, fi nal analyses were restricted to the 167,621 subjects aged 
30 – 89 years at the beginning of the follow-up, corresponding to 
5.0 % of the total regional population of the same age band. Of the 
cohort subjects, 54.6 % were men, 38.2 % were aged 30 – 64 years, 
32.6 % were aged 65 – 74 years, and 29.2 % were aged 75 – 89 years, 
respectively. Th ere were 473,374 person-years of follow-up in the 
period from 2008 to 2010, and 17,134 (10.2 % ) deaths occurred. 
 Th e crude mortality rate was higher in men than in women and, 
as expected, increased progressively with aging, reaching a crude 
mortality rate of 76.6 per 1,000 subjects among those aged 75 – 89 
years ( Table 1 ). 
 Th e main causes of death were cardiovascular diseases and neo-
plasms accounting for 34.6 % and 31.0 % of all deaths, respectively. 
CLD accounted for 2.3 % of total deaths, and they were responsi-
ble for about half (47.2 % ) of the mortality from digestive diseases. 
Notably, as shown in  Table 2 , the diabetic cohort had a signifi cantly 
greater mortality risk than the general population, with an overall 
SMR of 1.49 (95 % confi dence interval  =  1.46 – 1.52) in men and 
1.53 (1.49 – 1.56) in women, respectively. Th e excess in mortality of 
diabetic subjects with respect to the general population was much 
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larger among younger age classes. All the main causes of death 
showed a signifi cantly higher risk in diabetes ( Figure 2 ,  Table 2 ). 
Th e risk of dying from CLD was markedly increased among dia-
betic subjects with respect to the general population, with a SMR 
of 2.47 (2.19 – 2.78) for men and of 2.70 (2.24 – 3.23) for women. 
 When all diseases reported in death certifi cates were analyzed, 
CLD was mentioned as either a causing or a contributing factor in 
6.9 % of the total deaths that occurred in diabetic subjects. Th e 2.5-
fold relative risk estimated by analyses restricted to the underlying 
cause of death was confi rmed. Interestingly, as reported in  Table 3 , 
NVNA-related CLD, which represented about two-thirds of cases of 
all CLD-related deaths among diabetics, had a SMR of 2.86 (2.65 –
 3.08), whereas SMRs for virus-related and alcohol-related CLD 
were 2.17 (1.90 – 2.47) and 2.25 (1.98 – 2.54), respectively. As shown 
in  Table 4 , when the analysis of mortality from CLD was strati-
fi ed by sex and age, the SMRs for NVNA-related CLD remained 
the highest in all age classes and in both sexes. It is noteworthy that 
the SMR for NVNA-related CLD was higher in younger subjects 
(30 – 64 class of age) and decreased across the three classes of age. 
Also worth mentioning is that the SMR for NVNA-related CLD 
death was remarkably higher in women than in men. 
 Finally, when analyses were carried out in the sub-cohort with at 
least 7 years of diabetes duration, the estimated mortality risk for 
CLD only slightly decreased in the underlying cause of death anal-
ysis (SMR  =  2.33, 1.99 – 2.71), and remained unchanged in the mul-
tiple causes analysis both for all CLD (SMR  =  2.55, 2.34 – 2.77) and 
for NVNA-related CLD (SMR  =  2.89, 2.59 – 3.22, data not shown). 
 DISCUSSION 
 We and others have reported an increased mortality from CLD in 
diabetes ( 5,6 ). Th e results of the present study confi rm that dia-
betic persons have a two- to threefold increased risk of dying from 
CLD and, most importantly, point out that all main etiologies of 
CLD (e.g., virus, alcohol) contribute to this increased risk. How-
ever, the main result of our study is that the greater contribution 
to CLD mortality comes from NVNA-related CLD death, mainly 
represented by NAFLD. Th ey also include rarer causes such as toxic 
substances (e.g., drugs), autoimmunity, and hemocromatosis. 
 It is well known that most subjects with CLD not attributable to 
prior virus infection or alcohol abuse have NAFLD ( 15 ). It is also 
well known that most subjects with type 2 diabetes have NAFLD 
( 9,16 ). Th erefore, it is reasonable to assume that the largest frac-
tion of deaths we have coded as NVNA-related CLD were NAFLD-
related. In fact, NAFLD is not a benign condition but encompasses 
a large spectrum of hepatic disorders including fatty liver, steato-
hepatitis, and liver cirrhosis  (17), which confer an increased risk 
of dying not only from liver failure but also from cardiovascular 
disease and chronic kidney disease ( 7,9,18 ). When liver diseases 
reported in death certifi cates were carefully analyzed, we found 
that NVNA-related CLD was associated with higher SMRs than 
virus-related CLD or alcohol-related CLD (approximately three vs. 
two) and this result was observed in women more than in men and 
at all ages . Th ese fi ndings point out that prevention of liver disease 
should not target only viral infection or alcohol abuse by specifi c 
vaccination or educational campaigns but should also implement 
strategies aiming to reduce NAFLD. Th e latter should emphasize 
the need to avoid weight gain and to promote weight loss when 
necessary. It is well known, indeed, that fatty liver is strictly related 
to whole body fat excess, mainly in the visceral area ( 12 ). 
 Recent studies, mainly in the general population, reported that the 
presence of NAFLD carries an increased risk of overall mortality and 
of mortality related to cardiovascular disease and liver disease ( 19 –
 24,25 ). In the Dionysos cohort, a study of the Italian general population, 
the average prevalence of NAFLD was 55 % , with a 24.5 % prevalence 
in normal weight subjects (body mass index   <  25  kg / m 2 ) and of 91 % 
in obese subjects (body mass index   >  30  kg / m 2 ) ( 26 ). However, in 
Italy, the main reported causes of liver cirrhosis are HCV infection 
(51.1 % ) and alcohol consumption (12.4 % ), with other less represented 
etiologies being autoimmune hepatitis and primary biliary cirrhosis 
(2 % ), and the metabolic CLDs (2 % ) ( 27 ). Nonetheless, in Northern 
Italy the prevalence of HCV is lower and the proportion of CLD 
with an alcoholic etiology is higher than the national average ( 28 ). It 
must be remarked that the cirrhotic state is itself associated with an 
176,771
173,260
167,621
17,134
Diabetics identified in December 2007
209 With missing data
1,302 Dead during the last week of December
5,639 With age <30 or >89 years
Decedents during the 3-year follow-up
Diabetics with age between 30 and 89 years
Diabetics with complete data and alive
at 31 December, 2007
 Figure 1 .  Schematic design of the enrollment and follow-up of the diabetic 
subjects. 
 Table 1 .  Person-years, number of deaths, and crude mortality 
rates stratifi ed by sex and age classes of 167,621 diabetic 
subjects followed for 3 years 
  Person-years 
 Number of 
deaths 
 Crude mortality 
rate  × 1,000 subjects 
 Gender 
  Men  258,912  9,866  38.1 
  Women  214,463  7,268  33.9 
 Age class (years) 
  30 – 64  167,447  1,692  10.1 
  65 – 74  156,738  4,008  25.6 
  75 – 89  149,190  11,434  76.6 
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increased risk of diabetes because of its impact on glucose metabo-
lism; therefore, the increased mortality risk found for CLD in our 
study could be partly due to reverse causation (cirrhosis as a cause of 
diabetes). However, in spite of the rather short follow-up, we could 
identify a sub-cohort with long diabetes duration; in these subjects, 
the increased mortality risk found for CLD is less probable to be 
explained by diabetes developing from an advanced cirrhotic state. 
 Th erefore, considering also that NAFLD and diabetes are a 
growing health problem ( 29 – 32 ), we believe that our results may 
have important clinical implications. Our study has a number of 
strengths, which include the great number of subjects evaluated, 
the completeness of information about vital status, the careful 
analysis of all aspects of death certifi cates (e.g., comorbidities). We 
are not aware of a study with these merits. Th e study, however, has 
some limitations. We totally lack data on diabetes type, treatment, 
and complications. However, here the point is to compare diabetic 
and nondiabetic subjects rather than to discuss about the impact 
on the results of clinical features of diabetes. Th e main limitation, 
in fact, is related to potential underreporting of data, which might 
be useful to better defi ne the etiology of CLD, which was available 
in nearly half of the CLD deaths in the regional population, a fi g-
ure similar to US studies ( 13 ). For example, alcohol-related CLD 
could be particularly aff ected by underreporting alcohol abuse due 
to prejudices associated to this misbehavior. Yet, excessive alcohol 
intake could be a feature of the remote past of the subjects who died 
and not of the years immediately preceding their death and, for 
such reason, may be erroneously not reported in the death certifi -
cate. Again, viral hepatitis might have occurred several years before 
death and, for such reason, may not be reported in the death cer-
tifi cate. However, such underreporting has presumably occurred 
to a similar extent in death certifi cates of diabetic and nondiabetic 
patients. As to NVNA-related CLD, we have previously mentioned 
that this category is made essentially by NAFLD but that it also 
includes other etiologies (e.g., toxic substances, autoimmunity, 
hemocromatosis). Even though these etiologies might be slightly 
more frequent in diabetes, they are, however, rather uncommon. 
Th erefore, we feel that our data are solid enough to suggest an 
increased risk of mortality by NAFLD in diabetes. 
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 Figure 2 .  Age-standardized mortality rates (standard European population) 
for circulatory diseases, neoplasms, and chronic liver diseases among 
diabetics and the general population of the Veneto region aged 30 – 89 years. 
 Table 3 .  SMRs for CLDs reported as either the underlying or 
the contributing causes of death of 167,621 diabetic patients 
followed-up for 3 years 
  Number of deaths  SMR  95 % CIs 
 All CLD  1,183  2.55  2.41 – 2.70 
 Virus-related CLD a  234  2.17  1.90 – 2.47 
 Alcohol-related CLD a  260  2.25  1.98 – 2.54 
 NVNA-related CLD  707  2.86  2.65 – 3.08 
 CI, confi dence interval; CLD, chronic liver disease; NVNA, non-viral non-alcohol; 
SMR, standardized mortality ratio. 
 a 18 CLD deaths were classifi ed as related to both alcohol and viral hepatitis. 
 Table 2 .  SMR of 167,621 diabetic patients followed-up for 3 years: analysis of the underlying cause of death 
  Men  Women 
  n  SMR (CI)  n  SMR (CI) 
 All causes  9,866  1.49 (1.46 – 1.52)  7,268  1.53 (1.49 – 1.56) 
 All causes, 30 – 64  years  1,264  2.14 (2.03 – 2.27)  428  2.52 (2.28 – 2.77) 
 All causes, 65 – 74  years  2,881  1.69 (1.63 – 1.75)  1,127  1.82 (1.71 – 1.93) 
 All causes, 75 – 89  years  5,721  1.32 (1.29 – 1.36)  5,713  1.44 (1.40 – 1.48) 
 Cardiovascular diseases  3,206  1.47 (1.42 – 1.52)  2,674  1.46 (1.40 – 1.51) 
 Neoplasms  3,425  1.30 (1.26 – 1.34)  1,893  1.32 (1.26 – 1.38) 
 Diabetes  1,184  6.11 (5.77 – 6.47)  1,019  6.68 (6.28 – 7.10) 
 Respiratory diseases  511  1.14 (1.04 – 1.24)  314  1.21 (1.08 – 1.35) 
 Digestive diseases  471  1.86 (1.70 – 2.04)  373  1.76 (1.58 – 1.96) 
 Chronic liver diseases  278  2.47 (2.19 – 2.78)  120  2.70 (2.24 – 3.23) 
 CI, confi dence interval; SMR, standardized mortality ratio. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 It is known that mortality from chronic liver diseases in-
creases in diabetes. 
 3 The impact of different liver disease etiologies on mortality 
in diabetes is poorly documented. 
 WHAT IS NEW HERE 
 3 All the principal chronic liver disease etiologies examined 
in the present study increased the risk of mortality in 
diabetes. 
 3 Nonalcoholic fatty liver disease emerged as the most impor-
tant cause of mortality among the different etiologies.  
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 In conclusion, our study shows that diabetic patients are exposed 
to a two- to threefold increased risk of mortality from CLD. Th is 
increased risk mainly accounts for the hepatic insults apparently 
diff erent from those by classic viruses and alcohol. With the limi-
tations we have mentioned, the main cause of the excess mortal-
ity related to CLD seems to be attributable to NAFLD. For such 
reasons, strategies to prevent CLD-related deaths should include 
not only vaccination against viral hepatitis and education on the 
particularly deleterious eff ects of alcohol in diabetes but also eff ec-
tive campaigns to reduce body weight and avoid weight gain. An 
early diagnosis and treatment of NAFLD, if any, might also have a 
benefi cial clinical impact on the survival of diabetic patients. 
 CONFLICT OF INTEREST 
 Guarantor of the article : Giacomo Zoppini, MD, PhD. 
 Specifi c author contributions : U.F. and N.G. designed the study, 
collected and analyzed the data; G.Z. revised the results and wrote 
the manuscript; E.B., G.T., and M.S. critically revised the manu-
script. All authors have seen and approved the fi nal version of the 
submitted manuscript. 
 Financial support: None. 
 Potential competing interests: None. 
 Table 4 .  SMRs for CLDs reported as either the underlying or the contributing causes of death of 167,621 diabetic patients followed-up for 3 years 
  Men  Women 
  n  SMR (CI)  n  SMR (CI) 
 All ages 
  All CLD  825  2.54 (2.37 – 2.72)  358  2.58 (2.32 – 2.87) 
  Virus-related CLD a  124  2.28 (1.90 – 2.72)  110  2.05 (1.69 – 2.47) 
  Alcohol-related CLD a  222  2.25 (1.96 – 2.56)  38  2.26 (1.60 – 3.11) 
  NVNA-related CLD  495  2.78 (2.54 – 3.04)  212  3.07 (2.67 – 3.51) 
 30 – 64  years 
  All CLD  230  3.84 (3.36 – 4.37)  41  4.79 (3.44 – 6.50) 
  Virus-related CLD a  30  3.21 (2.16 – 4.58)  6  4.85 (1.77 – 10.6) 
  Alcohol-related CLD a  77  3.34 (2.63 – 4.17)  12  3.71 (1.91 – 6.47) 
  NVNA-related CLD  132  4.41 (3.69 – 5.23)  23  5.51 (3.49 – 8.26) 
 65 – 74  years 
  All CLD  329  2.51 (2.24 – 2.79)  100  3.17 (2.58 – 3.85) 
  Virus-related CLD a  52  2.60 (1.94 – 3.41)  31  3.27 (2.22 – 4.65) 
  Alcohol-related CLD a  81  1.93 (1.53 – 2.39)  17  2.72 (1.58 – 4.35) 
  NVNA-related CLD  198  2.82 (2.44 – 3.24)  54  3.31 (2.49 – 4.32) 
 75 – 89  years 
  All CLD  266  1.99 (1.76 – 2.24)  217  2.21 (1.92 – 2.52) 
  Virus-related CLD a  42  1.69 (1.22 – 2.28)  73  1.70 (1.33 – 2.14) 
  Alcohol-related CLD a  64  1.90 (1.47 – 2.43)  9  1.23 (0.56 – 2.34) 
  NVNA-related CLD  165  2.12 (1.81 – 2.47)  135  2.78 (2.33 – 3.28) 
 CI, confi dence interval; CLD, chronic liver disease; NVNA, non-viral non-alcohol; SMR, standardized mortality ratio. 
 a 18 CLD deaths were classifi ed as related to both alcohol and viral hepatitis. 
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